Oxford Expression Technologies (OET) and Eden Biodesign have signed a co-marketing agreement.
Under the terms of the agreement, OET will offer its customers access to Eden Biodesign's process development, clinical trial cGMP manufacturing and analytical development services.
In return, Eden Biodesign's customers will have access to OET's range of baculovirus capabilities to meet individual protein expression requirements.
OET customers will benefit from a smooth transition between optimisation of expression and cGMP production and scale-up and the ability to transfer projects intended for clinical development to Eden Biodesign's process development, cGMP manufacturing and analytical development services.
Eden Biodesign's customers can take advantage of OET's experience in troubleshooting baculovirus expression; the use of flashBACTM technology to increase protein yield in difficult-to-express proteins; and the development of a protocol for optimal expression of proteins.
Oxford Expression Technologies provides baculovirus-based protein expression products and services.
Eden Biodesign provides biopharmaceutical process development and cGMP manufacturing services.
